Mir-132 directly silences ZEB2, thus attenuating EMT, invasion and metastasis in colorectal [164] and lung [165] cancers, and reduces EMT and migratory/invasive capacity of human non-small cell lung carcinoma (NSCLC) through the EMT-related TGF-β1/Smad2 pathway [166]. The gene discussed is SMAD2; the disease is non-small cell lung carcinoma.